PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.

ABSTRACT:

Introduction

Thymic epithelial tumors (TETs) are rare tumors originating from the epithelium of the thymus with limited therapeutic options beyond surgery. The pathogenesis of TETs is poorly understood, and the scarcity of model systems for these rare tumors makes the study of their biology very challenging.

Methods

A new cell line (MP57) was established from a thymic carcinoma specimen and characterized using standard biomarker analysis, as well as next-generation sequencing (NGS) and functional assays. Sanger sequencing was used to confirm the mutations identified by NGS.

Results

MP57 possesses all the tested thymic epithelial markers and is deemed a bona fide thymic carcinoma cell line. NGS analysis of MP57 identified a mutation in the gene PIK3R2, which encodes a

SUBMITTER: Alberobello AT 

PROVIDER: S-EPMC5319212 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature